Knight Therapeutics Inc. (TSX:GUD)
12.06
+0.01 (0.08%)
Nov 13, 2026, 4:00 PM EST
Knight Therapeutics Revenue
Knight Therapeutics had revenue of 137.69M CAD in the quarter ending September 30, 2026, with 13.28% growth. This brings the company's total for the last twelve months to 563.45M, up 36.15% year-over-year. In the year 2025, Knight Therapeutics had annual revenue of 450.09M with 21.22% growth. That makes Knight Therapeutics the 12,705th largest company in the world by revenue and 283rd in Canada.
Revenue (ttm)
563.45M
Revenue Growth
+36.15%
P/S Ratio
2.10
Revenue / Employee
678.85K
Employees
830
Market Cap
1.19B
Revenue by Geography
- Brazil 182.52M 40.6%
- Canada 84.28M 18.7%
- Colombia 55.00M 12.2%
- Rest of The Latin America 43.02M 9.6%
- Argentina 40.75M 9.1%
- Mexico 24.50M 5.4%
- Other 20.02M 4.4%
Fiscal year ended Dec 31, 2025 See the full Knight Therapeutics breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 450.09M | 78.78M | 21.22% |
| Dec 31, 2024 | 371.30M | 43.11M | 13.13% |
| Dec 31, 2023 | 328.20M | 34.64M | 11.80% |
| Dec 31, 2022 | 293.56M | 50.09M | 20.57% |
| Dec 31, 2021 | 243.48M | 43.96M | 22.03% |
| Dec 31, 2020 | 199.52M | 152.06M | 320.39% |
| Dec 31, 2019 | 47.46M | 34.96M | 279.69% |
| Dec 31, 2018 | 12.50M | 3.87M | 44.78% |
| Dec 31, 2017 | 8.63M | 2.69M | 45.35% |
| Dec 31, 2016 | 5.94M | 4.90M | 472.81% |
| Dec 31, 2015 | 1.04M | 672.00K | 184.11% |
| Dec 31, 2014 | 365.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Curaleaf Holdings | 1.92B |
| Green Thumb Industries | 1.76B |
| Verano Holdings | 1.20B |
| Cresco Labs | 924.67M |
| Vireo Growth | 611.54M |
| Aurora Cannabis | 314.07M |
| Canopy Growth | 308.32M |
| Cronos Group | 292.73M |
Knight Therapeutics News
- 2 days ago - Knight Therapeutics Inc. named one of Quebec's Top Growing Companies in The Globe and Mail's inaugural ranking, with 53% three-year revenue growth - GlobeNewsWire
- 7 days ago - What Knight Therapeutics (GUD) Said on Its Q3 Earnings Call - MarketBeat
- 9 days ago - Knight Therapeutics price target raised to C$13 from C$11 at RBC Capital - TheFly
- 9 days ago - Knight Therapeutics price target raised to C$12.75 from C$12.25 at Stifel - TheFly
- 9 days ago - Knight Therapeutics price target raised to C$12.75 from C$11 at Canaccord - TheFly
- 10 days ago - Knight Therapeutics Inc. Q3 Loss Narrows - Nasdaq
- 11 days ago - Knight Therapeutics Earnings Call Transcript: Q3 2026 - Transcripts
- 11 days ago - Knight Therapeutics Earnings release: Q3 2026 - Filings